<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; Exela</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/tag/exela/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Teva introduces Nicardipine HCl Injection in US</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2008/09/24/teva-introduces-nicardipine-hcl-injection-in-us/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2008/09/24/teva-introduces-nicardipine-hcl-injection-in-us/#comments</comments>
		<pubDate>Wed, 24 Sep 2008 08:06:49 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[Blood pressure]]></category>
		<category><![CDATA[Cardene® I.V.]]></category>
		<category><![CDATA[EKR Therapeutics]]></category>
		<category><![CDATA[Exela]]></category>
		<category><![CDATA[hypertension]]></category>
		<category><![CDATA[injection]]></category>
		<category><![CDATA[Nicardipine HCl Injection]]></category>
		<category><![CDATA[Teva]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/2008/09/24/teva-introduces-nicardipine-hcl-injection-in-us/</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. has introduced its  Nicardipine Hydrochloride Injection, 2.5 mg/mL, in the United States of America. The injection is the first alternative to EKR Therapeutics&#8217; treatment for high blood pressure, Cardene® I.V. According to IMS sales data, this product had annual sales of approximately $181 million in the United States from July 2007 [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2008/09/teva.png" align="left" height="75" hspace="5" vspace="5" width="200" /><a href="http://www.tevapharm.com/">Teva Pharmaceutical</a> Industries Ltd. has introduced its  Nicardipine Hydrochloride Injection, 2.5 mg/mL, in the United States of America. The injection is the first alternative to EKR Therapeutics&#8217; treatment for high blood pressure, Cardene® I.V. According to IMS sales data, this product had annual sales of approximately $181 million in the United States from July 2007 to June 2008. As part of an agreement that Teva and Exela PharmSci, Inc. (a Reston, Virginia based company developing pharmaceuticals), entered into, Teva is licensed to manufacture and distribute the  Nicardipine HCl Injection.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2008/09/24/teva-introduces-nicardipine-hcl-injection-in-us/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
